Real-world clinical outcomes of nivolumab and taxane as a second- or later-line therapy for recurrent or unresectable advanced esophageal squamous cell carcinoma

BACKGROUND: Nivolumab is approved in Japan as a second-line treatment for patients with advanced esophageal squamous cell carcinoma (ESCC) resistant to fluoropyrimidine and platinum-based drugs. It is also used in adjuvant and primary postoperative therapies. This study aimed to report real-world da...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohsawa, Manato, Hamai, Yoichi, Emi, Manabu, Ibuki, Yuta, Kurokawa, Tomoaki, Yoshikawa, Toru, Hirohata, Ryosuke, Kitasaki, Nao, Okada, Morihito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151017/
https://www.ncbi.nlm.nih.gov/pubmed/37139161
http://dx.doi.org/10.3389/fonc.2023.1126536

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151017/
https://www.ncbi.nlm.nih.gov/pubmed/37139161
http://dx.doi.org/10.3389/fonc.2023.1126536

Ejemplares similares